Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K4 | P45985 | 20/20 | 1.00 |
| ▸ | MAP2K7 | O14733 | 7/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22819390 | 0.90 | MAP2K4 (1.00) | MAP2K4MAP2K7 | |
| SCHEMBL27191602 | 0.83 | MAP2K4 (1.00) | MAP2K4MAP2K7 | |
| SCHEMBL27191586 | 0.82 | MAP2K4 (1.00) | MAP2K4MAP2K7 | |
| SCHEMBL1461049 | 0.80 | MAP2K4 (0.67) | MAP2K4MAP2K7 | |
| SCHEMBL27191580 | 0.79 | MAP2K4 (1.00) | MAP2K4MAP2K7 | |
| SCHEMBL27191600 | 0.79 | MAP2K4 (1.00) | MAP2K4MAP2K7 | |
| SCHEMBL27191606 | 0.79 | MAP2K4 (1.00) | MAP2K4MAP2K7 | |
| SCHEMBL21046972 | 0.79 | MAP2K4 (0.65) | MAP2K4MAP2K7 | |
| SCHEMBL22819378 | 0.78 | MAP2K4 (1.00) | MAP2K4MAP2K7 | |
| SCHEMBL5381750 | 0.77 | MAP2K4 (0.68) | MAP2K4MAP2K7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240116875-A1 | RATIONAL DESIGN, OPTIMIZATION, AND BIOLOGICAL EVALUATION OF NOVEL MEK4 INHIBITORS AGAINST PANCREATIC ADENOCARCINOMA | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-04-11 | — | — | US | disclosed |
| US-11370770-B2 | 3-arylindazoles as selective MEK4 inhibitors | NORTHWESTERN UNIVERSITY (US) | 2022-06-28 | — | — | US | disclosed |
| US-20200399241-A1 | 3-ARYLINDAZOLES AS SELECTIVE MEK4 INHIBITORS | NORTHWESTERN UNIVERSITY (US) | 2020-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240116875-A1 | RATIONAL DESIGN, OPTIMIZATION, AND BIOLOGICAL EVALUATION OF NOVEL MEK4 INHIBITORS AGAINST PANCREATIC ADENOCARCINOMA | MAPK4, MAP4K3, MAP3K4 | MAP2K4 36/4885MAP2K7 38/4885 |
| US-20200399241-A1 | 3-ARYLINDAZOLES AS SELECTIVE MEK4 INHIBITORS | MAP4K3, MAPK4, MAP3K4 | MAP2K4 39/4885MAP2K7 35/4885 |
| US-11370770-B2 | 3-arylindazoles as selective MEK4 inhibitors | MAP4K3, MAPK4, MAP3K4 | MAP2K4 39/4885MAP2K7 35/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.